Close Menu

hypertriglyceridemia

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced new preclinical data demonstrating the delivery capabilities of its GalNAc conjugate technology in its hypercholesterolemia and hypertriglyceridemia programs.

The researchers identified an accumulation of rare variants in four genes identified by GWAS. They now plan to sequence more candidate genes using Sanger sequencing and, eventually, next-generation sequencing.

Using genome-wide association and targeted re-sequencing studies, a Canadian-led research team has uncovered common and rare genetic variants in four genes that are over-represented in individuals with extremely high blood triglyceride levels.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.